During the period from 2016 to the first quarter of 2017 the FSUE Moscow Endocrine Plant in accordance with the implementation program registered 7 drugs.
Registration certificates for the drugs Tramadol 50 mg capsules, Levofloxacin 0.5% eye drops, Bupraxon® sublingual tablets, Midazolam 5 mg / ml solution for intravenous and intramuscular administration were received.
The drug Midazolam was developed as part of the federal target program "Development of the pharmaceutical and medical industry of the Russian Federation for the period up to 2020 and the future perspective", in which the Enterprise is an active participant.
As part of the contract production the Enterprise is a developer and manufacturer of the drug PAMBA 10 mg / ml solution for intravenous and intramuscular injection, registered in 2016 by LLC PROFITFARM.
In Q1 2017 the registration of the drug Tropicamide 0.5% and 1% eye drops, also developed as part of the Pharma 2020 program, and the drug Clozapine 25 mg and 100 mg tablets was completed.
By the end of 2017, the Enterprise plans to complete the registration of 4 new own drugs, as well as to receive 3 registration certificates of drugs for production at the facilities of the Enterprise.
Comment type is not specified in the component properties.